CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE, Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced its first half of 2023 financial results...

Related Keywords

Japan ,Malaysia ,China ,National University Hospital ,Singapore General ,Singapore ,Peter Choo ,Cytomed Or Company ,Linkedin ,Health Sciences Authority ,Cytomed Therapeutics Limited ,Agency For Science ,Facebook ,Nasdaq ,Good Manufacturing Practice ,Six Months Ended June ,Public Offering ,Cash Equivalents ,